C-S-H中Al3+离子的固溶对表面吸附碱量的影响

研究了Al3+离子的固溶对C-S-H表面吸附Na+离子量的影响.实验结果表明,Al3+离子固溶于C-S-H结构中将使C-S-H表面所带的负电量增大,因而也就增大了C-S-H表面对Na+离子的吸附能力.     

Influence of hydrochlorothiazide on the pain threshold and on the antinociceptive activity of morphine,in rats

Summary Hydrochlorothiazide, acutely injected in rats, has a weak analgesic activity per se and potentiates and prolongs the antinociceptive effect of morphine.This work was supported in part by grants from Consiglio Nazionale delle Ricerche, and by Ministero della Pubblica Istruzione, Roma.     

Elaboration and Properties of Nanocomposite Structures Based on Crown Modified Platinum Nanoparticles

1 Results This paper presents the development of platinum nanocomposites structures based on organically modified c.a.2 nm core platinum nanoparticles.The chemical modification of the 4-mercaptoaniline functionalized particles by various in coming molecules is evidenced and precisely quantified.The particles can be dissolved like molecules in various solvents depending on the features of the new crown and X-rays shows that the interparticle distance is affected by the crown modification.These platinum n...     

The Three-component One-pot Synthesis of 4,6-Diarylpyrimidin-2(1h)-ones and 9-Phenyl-8-oxa-10,12-diaza-tricyclo[7.3.1.0~(2,7)]trideca-2(7),3,5-trien-11-one

1 Results Pyrimidinones (PMs) are a class of important heterocycles which have been well documented throughout the literature due to their biological importance. They exhibit a wide range of pharmaceutical and therapeutic properties[1].A rapid and efficient one-pot method for the synthesis of 4,6-diarylpyrimidin-2(1H)- ones and related heterocycles is described.The condensation of acetophenone derivatives,aldehydes and urea in the presence of sulfamic acid was employed to synthesize a variety of pyrimid...     

浅谈新型墙体材料——煤矸石空心砖

煤矸石空心砖是一种新型环保墙体材料，符合国家及山西省出台的限制生产和使用实心黏土砖，鼓励发展新型建筑材料的政策。利用煤矸石制造的空心砖可以作为保温材料，既可节约建筑能耗，又可节约土地资源，减少环境污染。煤矸石空心砖同黏土实心砖相比，具有高强、轻质、隔音、隔热、保温、防震等优点，市场前景良好。     

Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics.

Obese postmenopausal female volunteers were given timed daily oral dosages of bromocriptine, and tested for reduction of body fat stores. This dopamine agonist has been shown to reset circadian rhythms that are altered in obese animals and to reduce body fat levels in several animal models. The participants were instructed not to alter their existing exercise and eating behavior during treatment. Skinfold measurements were taken on 33 subjects as indices of body fat. The measurements (e.g., suprailiac) were reduced after six weeks by about 25%, which represents a reduction of 11.7% of the total body fat. These dramatic decreases in body fat, which are equivalent to that produced by severe caloric restriction, were accompanied by more modest reductions of body weight (2.5%), indicating a possible conservation of protein that is usually lost as a consequence of such caloric restriction. The effects of bromocriptine treatment on body fat and hyperglycemia were also examined in non-insulin dependent diabetics being treated with oral hypoglycemics (7 subjects) or insulin (7 subjects). Total body fat was reduced by 10.7% and 5.1% in diabetics on oral hypoglycemics and insulin, respectively, without any significant reductions in body weight. Hyperglycemia was reduced in most of the 15 diabetic subjects treated leading to euglycemia and even cessation of hypoglycemic drugs in 3 of the 7 subjects during 4-8 weeks of bromocriptine treatment. These findings support the hypothesis that obesity and type II diabetes may be treated effectively with bromocriptine when administered at the proper times and dosages.